Bispecific Antibody Engineering
Antibody Engineering: Bispecific antibody platforms
The dual target antibody platform technology of PharmAbcine is based on the fully human antibody candidates selected from HuPhage biopanning process. Depending on antigen presentation patterns on target cell types and the related drug MOA, various bispecific platforms (DIG-body, PIG-body and TIG-body) are adopted in our antibody engineering strategy. Currently, immuno-oncology assets like PMC-122a (anti-PD-L1 x SIRPa) and PMC-122b (anti-PD-L1 x anti-CD47) are currently under early development stage.
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVE